The U.S. Department of Justice has turned the tables on cannabis prohibitionist groups challenging the federal rescheduling of marijuana to Schedule III, arguing in a July 2 court filing that the groups' opposition is driven not by public health concerns but by direct financial self-interest in maintaining a Schedule I designation. The DOJ's response, filed in the U.S. Court of Appeals for the District of Columbia Circuit, challenges whether two of the nine anti-rescheduling petitioners - the National Drug and Alcohol Screening Association and pharmaceutical aspirant MMJ International Holdings - even have legal standing to contest the April 2026 order issued by Acting Attorney General Todd Blanche. For licensed cannabis operators and compliance professionals tracking the federal regulatory timeline, this development matters considerably: it signals that the DOJ is prepared to aggressively defend rescheduling on both substantive and procedural grounds.
The DOJ's position cuts directly against the narrative these groups have constructed. NDASA, which advocates for drug-free workplace programs, argued that a Schedule III federal listing for state-licensed medical cannabis would force its members - employers and medical review officers who interpret drug-test results - to overhaul existing testing protocols at unrecoverable cost. MMJ International Holdings, which holds an active DEA Schedule I analytical laboratory registration and claims to have invested $10 million and eight years of work toward FDA-approved cannabinoid-based drugs, argued that rescheduling would upend its competitive position before it has brought a single product to market. The irony is hard to miss: a company with no authorized product is claiming competitor standing against an industry it hasn't yet entered. For operators in mature regulated markets - where tracking compliance requirements through tools like a Michigan cannabis POS system is table stakes - the idea that a non-competitor can assert market harm is a legally thin argument, and the DOJ said as much.
The department's legal team framed both challengers as invoking what it called "pocketbook interests served by keeping all marijuana in Schedule I." That phrase is worth sitting with. The Controlled Substances Act, the DOJ argued, was enacted to protect the health and welfare of the American public and to ensure legitimate medical and scientific access to controlled substances - not to guarantee a revenue stream for workplace drug-testing vendors, and certainly not to insulate a pharmaceutical startup from future market competition. The DOJ drew a sharp line: drug screeners, employers who screen for drugs, and a company with no market presence are not the intended beneficiaries of the CSA, and their financial preferences for categorical Schedule I control place them outside the statute's "zone of interests."
The Standing Problem NDASA and MMJ Cannot Sidestep
Article III standing requires a concrete, particularized injury - not a general business inconvenience or a speculative future competitive disadvantage. The DOJ argued that NDASA failed to identify concrete harm to any specific individual member, relying instead on generalized assertions about cost burdens across its membership. MMJ's standing argument fares even worse on the DOJ's reading: a company that has not yet produced an authorized product cannot claim competitor standing against businesses operating in a market it has not yet entered. These are not minor procedural quibbles. If the D.C. Circuit agrees that neither petitioner has standing, the stay motion fails before the court ever reaches the merits of the rescheduling order itself.
There is also the treaty question. NDASA and MMJ argued that Blanche exceeded his authority by rescheduling cannabis without adequately addressing U.S. obligations under the Single Convention on Narcotic Drugs. The DOJ's response pointed to the 2024 opinion from the DOJ's Office of Legal Counsel, which concluded that placing cannabis in Schedule III satisfies U.S. treaty compliance - and that the attorney general holds authority to issue a scheduling order "without regard to" standard formal rulemaking procedures when acting under the relevant treaty provision. The DOJ also noted that the Department of Health and Human Services had already recommended Schedule III placement based on its own medical and scientific review, giving the acting attorney general an authoritative foundation for the April 2026 order.
What This Means for the Cannabis Business Community
For licensed operators - dispensaries, cultivators, processors, and the supply chain businesses that serve them - the DOJ's posture here is meaningful in ways that go beyond litigation strategy. A Schedule III designation carries real operational consequences. It would not automatically federalize cannabis sales or eliminate state-by-state licensing regimes, but it would remove cannabis from the 280E tax classification that has long prevented plant-touching businesses from deducting ordinary business expenses. That alone represents a significant shift in dispensary economics. Operators who have spent years structuring their businesses around 280E exposure understand exactly what is at stake.
The DOJ's willingness to name the financial motivations of the opposition groups plainly - in a formal federal court filing - also sends a signal to the broader regulated cannabis industry. The government is not treating rescheduling as a political concession. It is defending the order on statutory grounds, public health rationale, and procedural authority. That is a different posture than the cannabis industry has historically encountered from federal regulators, and it matters for how operators, investors, and multistate operators should be reading the federal timeline right now. The underlying lawsuit, which seeks to vacate the Schedule III order entirely, still awaits briefing and judicial review. Nothing is settled. But the DOJ's July 2 filing is the clearest signal yet that the federal government intends to defend this rescheduling order with considerable force.
The prohibitionist groups framed their challenge as a defense of public health. The DOJ's response, point by point, reframed it as a defense of market position. Courts will decide which framing holds.
